Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

Nevertheless, the rise in the Statutory Scheme rate to almost a third of pharma company revenue – which brings the average ...

Nuvectis Pharma, Inc. ("Nuvectis”, "Company”), a biopharmaceutical company focused on the development of innovative precision ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.

Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.